Los Angeles, CA - CBio was present at SoCal Taiwanese Biotechnology Symposium last July 7-8 at the Ackerman Grand Ballroom at the University of California, Los Angeles (UCLA). The event, hosted by SoCal Taiwanese Biotechnology Association, promotes the local biotechnology community, provides networking opportunity and exposure for small to medium-sized start-ups, and fosters connections between large firms and small start-ups.
David Charlot, PhD, CEO of CBio, chaired the Entrepreneur Panel with founders and executives of biotech companies. CBio also showcased the cellPhoresis™ technology on a booth where industrial and academic professionals learned more about CBios’s Bias-Free Live Cell Analysis.
About Dr. Charlot
David is an experienced inventor, entrepreneur, and manager with 15 years experience building tools to solve challenges in human health. He is a knowledgeable bioengineer with specialization in automation and systems integration for live cell analysis. He received his PhD in bioengineering from University of California, San Diego and BSc in physics from Delaware State University. David has 18 device patents for DNA and Cell Analysis issued in the US.
As CEO of CBio, David leads a multidisciplinary team to implement his vision to provide access to novel tools clinicians and researchers need to detect treatable disease early. His core passions are providing access to advanced live cell analysis tools and expanding opportunities in STEM education. He believes empowering the next generation of researchers with disruptive technology will spark their creativity and reshape the future of clinical diagnostics.
CBio is a life science tools company equipping researchers and clinicians with tools to help them identify predictive signatures of disease. Our proprietary cellPhoresis™ platform enables the study of living cells. Our technology identifies subtle differences between Normal and Abnormal living cells, preserves function, and retains usability for further study.